SEQUENTIAL

📍 New York City, United States👥 21 employees💰 Last funded Apr 2026
Biotechnology Research🌐 sequential.bio
Website LinkedIn
Sequential advances personal care and health research by studying the real-world impact of products through human clinical testing, biomarker discovery, and next-generation formulations across skin, scalp, oral, and vaginal care. Our end-to-end, in-house platform, from study design and participant recruitment (tailored to any required criteria) to laboratory analysis and data interpretation, turns complex biological data into clear, actionable insights. By combining microbial and molecular analyses, we enable the development of credible, effective, and trustworthy products and claims. With a database of over 50,000 samples, 4,000+ ingredients, and 10,000+ participants worldwide, Sequential leverages years of scientific expertise to set the standard for data-driven innovation and product validation in the personal care and pharmaceutical industries.
2
Total investors
1
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in SEQUENTIAL?
SEQUENTIAL has 2 investors on record on gritt.io, including 1 early-stage backers.
When did SEQUENTIAL last raise funding?
The most recent investment in SEQUENTIAL recorded on gritt.io was in April 2026.
What industry is SEQUENTIAL in?
SEQUENTIAL operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is SEQUENTIAL based?
SEQUENTIAL is headquartered in New York City, United States.